Clinical Trial: A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07137598) titled 'A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)' on Aug. 15.

Brief Summary: This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.

Study Start Date: Nov. 09, 2025

Study Type: INTERVENTIONAL

Condition: Rheumatoid Arthritis

Intervention: DRUG: Afimkibart

A...